Acadian Asset Management’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Acadian Asset Management’s Portfolio ODT Stock Details ODT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-384,995	Closed	-$506K	–	1930
2022 Q1	$506K	Sell	384,995 -31,744	-8%	-$39.8K	﹤0.01%	991
2021 Q4	$561K	Buy	416,739 +51,186	+14%	+$121K	﹤0.01%	983
2021 Q3	$1.06M	Buy	365,553 +2,091	+0.6%	+$6.95K	﹤0.01%	834
2021 Q2	$1.27M	Sell	363,462 -32,852	-8%	-$113K	﹤0.01%	846
2021 Q1	$1.35M	Buy	+396,314	New	+$7.49M	0.01%	865

Acadian Asset Management's ODT Position: Q2 2022 in Review

Acadian Asset Management sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q2 2022, closing a stake of 384,995 shares — an estimated $506K sold.

Acadian Asset Management first reported a position in ODT in Q1 2021 and held it in 5 quarters. The position peaked at $1.35M in Q1 2021. 0 funds tracked by Wall St. Rank hold ODT as of Q2 2022.

Acadian Asset Management reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Acadian Asset Management sold 384,995 Odonate Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $506K.
Acadian Asset Management first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
Acadian Asset Management's Odonate Therapeutics, Inc. Common Stock position peaked at $1.35M in Q1 2021.
0 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Acadian Asset Management's 13F filing for Q2 2022, filed 9 Aug 2022.